<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  
  <!-- Updated title and meta description for SEO -->
  <title>N‑Methyl‑Cyclazodone (NMC) Assessment: Pharmacology, Toxicology, Legal Context | Gemini Deep Research</title>
  <meta name="description" content="Evidence‑based overview of N‑Methyl‑Cyclazodone (NMC): LC‑MS and HPLC‑UV methods, inferred catecholaminergic mechanism, hepatotoxicity risk, acute toxicity case, legal status, and full PDF by Gemini Deep Research." />
  <meta name="author" content="Gemini Deep Research" />
  
  <!-- Search engine verification placeholders - replace with actual tokens -->
  <meta name="google-site-verification" content="GOOGLE_VERIFY_TOKEN" />
  <meta name="msvalidate.01" content="BING_VERIFY_TOKEN" />
  
  <!-- Canonical link -->
  <link rel="canonical" href="https://baftastic.github.io/nmc-analysis/" />
  
  <!-- Open Graph and Twitter meta tags -->
  <meta property="og:title" content="N‑Methyl‑Cyclazodone (NMC) Assessment | Gemini Deep Research" />
  <meta property="og:description" content="Concise scientific overview, safety warnings, and full PDF report by Gemini Deep Research." />
  <meta property="og:type" content="website" />
  <meta property="og:url" content="https://baftastic.github.io/nmc-analysis/" />
  <!-- Add an og:image URL if available -->
  <!-- <meta property="og:image" content="https://baftastic.github.io/nmc-analysis/assets/og-image.png" /> -->
  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="N‑Methyl‑Cyclazodone (NMC) Assessment" />
  <meta name="twitter:description" content="Overview and full report by Gemini Deep Research." />

  <!-- JSON-LD structured data to reinforce organization and website info -->
  <script type="application/ld+json">
  {
    "@context":"https://schema.org",
    "@type":"Organization",
    "name":"Gemini Deep Research",
    "url":"https://baftastic.github.io/nmc-analysis/",
    "contactPoint":[{"@type":"ContactPoint","email":"pharmacology@catom.dev","contactType":"customer service"}]
  }
  </script>
  <script type="application/ld+json">
  {
    "@context":"https://schema.org",
    "@type":"WebSite",
    "name":"N‑Methyl‑Cyclazodone (NMC) Assessment",
    "url":"https://baftastic.github.io/nmc-analysis/",
    "publisher":{"@type":"Organization","name":"Gemini Deep Research"}
  }
  </script>

  <style>
    :root {
      --text: #1a1a1a;
      --muted: #555;
      --bg: #fff;
      --accent: #0b5fff;
      --accent-contrast: #fff;
      --warn-bg: #fff3f3;
      --warn-border: #e53935;
      --card: #f8f9fb;
    }
    body {
      margin: 0;
      font-family: system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, sans-serif;
      color: var(--text);
      background: var(--bg);
      line-height: 1.55;
    }
    header {
      padding: 3rem 1rem 1rem;
      max-width: 860px;
      margin: 0 auto;
    }
    h1 {
      margin: 0 0 .5rem;
      font-size: 2rem;
      line-height: 1.2;
    }
    .byline {
      color: var(--muted);
      margin-bottom: 1rem;
    }
    .lede {
      font-size: 1.05rem;
      color: var(--muted);
      margin-top: .25rem;
    }
    main {
      padding: 1rem;
      max-width: 860px;
      margin: 0 auto 3rem;
    }
    section {
      background: var(--card);
      border-radius: 10px;
      padding: 1rem 1.25rem;
      margin: 1rem 0;
    }
    h2 {
      font-size: 1.25rem;
      margin: .25rem 0 .75rem;
    }
    ul {
      margin: .5rem 0 .5rem 1.25rem;
    }
    li {
      margin: .35rem 0;
    }
    .warn {
      background: var(--warn-bg);
      border: 1px solid var(--warn-border);
      color: #b71c1c;
    }
    .grid {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: .85rem;
    }
    .button {
      display: inline-block;
      background: var(--accent);
      color: var(--accent-contrast);
      padding: .75rem 1rem;
      border-radius: 8px;
      text-decoration: none;
      font-weight: 600;
      margin-right: .75rem;
      cursor: pointer;
    }
    .small {
      font-size: .95rem;
      color: var(--muted);
    }
    nav.small {
      margin-bottom: 1rem;
      font-size: 0.9rem;
      color: var(--muted);
    }
    nav.small a {
      color: var(--accent);
      text-decoration: none;
      margin-right: 12px;
    }
    nav.small a:hover, nav.small a:focus {
      text-decoration: underline;
    }
    footer {
      border-top: 1px solid #eee;
      padding: 1.5rem 1rem 3rem;
      max-width: 860px;
      margin: 0 auto;
      color: var(--muted);
      font-size: .95rem;
    }
    @media (max-width: 720px) {
      .grid { grid-template-columns: 1fr; }
    }
  </style>
</head>
<body>
  <header>
    <h1>N‑Methyl‑Cyclazodone (NMC)</h1>
    <div class="byline">A pharmacological and toxicological assessment • By <strong>Gemini Deep Research</strong></div>
    <p class="lede">Concise overview of a novel psychoactive stimulant analogue of Cyclazodone. Includes analytical methods, inferred mechanism, key risks, legal context, and link to the full report.</p>

    <!-- New: Table of Contents navigation for SEO and UX -->
    <nav aria-label="Contents" class="small">
      <a href="#safety">Safety</a>
      <a href="#highlights">Executive highlights</a>
      <a href="#methods">Analytical methods</a>
      <a href="#identifiers">Identifiers</a>
      <a href="#legal">Legal and safety context</a>
      <a href="#download">Download PDF</a>
    </nav>

    <!-- New: Text anchor for PDF for SEO -->
    <p>
      Download the full report: 
      <a href="./N-Methyl-Cyclazodone-Human-Use-Analysis.pdf">
        N‑Methyl‑Cyclazodone (NMC): Pharmacological and Toxicological Assessment (PDF)
      </a>
    </p>
  </header>

  <main>
    <section id="safety" class="warn">
      <h2>Critical safety notice</h2>
      <p>
        N‑Methyl‑Cyclazodone (NMC) may pose a risk of severe, idiosyncratic hepatotoxicity consistent with its oxazolidinone class lineage (e.g., pemoline). Acute toxicity has included multi‑system effects in a documented case. Content is provided for research and public health awareness; it is not medical advice.
      </p>
    </section>

    <section id="highlights">
      <h2>Executive highlights</h2>
      <ul>
        <li>Compound: N‑Methyl‑Cyclazodone (NMC), an oxazolidinone stimulant and analogue of Cyclazodone.</li>
        <li>Use context: Discussed online as a functional stimulant/nootropic; unscheduled “research chemical” status in many jurisdictions.</li>
        <li>Mechanism (inferred): Catecholaminergic stimulant activity involving DAT/NET reuptake inhibition and/or release; N‑demethylation to Cyclazodone observed in human case analysis.</li>
        <li>Primary risk: Potential for rare but severe, unpredictable liver injury (idiosyncratic hepatotoxicity), analogous to pemoline’s risk profile.</li>
        <li>Acute toxicity: Documented overdose presented with severe sympathomimetic features, neurological toxicity (choreoathetosis), ECG conduction abnormalities, rhabdomyolysis, and acute liver injury.</li>
        <li>Interactions: Likely CYP-mediated metabolism; inhibitors (e.g., certain antidepressants) may elevate exposure and risk.</li>
        <li>Legal context: Often unscheduled but may fall under analogue/psychoactive laws; monitored within EU EWS; UK covers under Psychoactive Substances Act.</li>
      </ul>
    </section>

    <section id="methods" class="grid">
      <div>
        <h2>Analytical methods</h2>
        <ul>
          <li>Identity: LC‑MS</li>
          <li>Purity: HPLC‑UV</li>
          <li>Purity caveat: “% area by UV” differs from assay by weight; vendor claims may not reflect absolute content.</li>
        </ul>
      </div>
      <div id="identifiers">
        <h2>Identifiers</h2>
        <ul>
          <li>Common names: N‑Methyl‑Cyclazodone, NMC</li>
          <li>CAS: 14461‑92‑8</li>
          <li>PubChem CID: 156614124</li>
          <li>Class: 5‑phenyl‑4‑oxazolidinone stimulant</li>
        </ul>
      </div>
    </section>

    <section id="legal">
      <h2>Legal and safety context (brief)</h2>
      <p class="small">
        NMC is generally not explicitly scheduled in many jurisdictions but may be controlled under analogue or psychoactive-substance laws. EU Early Warning System has recorded related notifications; the UK’s Psychoactive Substances Act broadly prohibits supply for human consumption. Availability, labeling, and compliance vary. This report does not provide legal advice.
      </p>
    </section>

    <section id="download">
      <h2>Download the full report (PDF)</h2>
      <p>
        The PDF provides detailed pharmacology, toxicology, case analysis, SAR rationale, and regulatory review.
      </p>
      <p>
        <a class="button" href="./N-Methyl-Cyclazodone-Human-Use-Analysis.pdf" download>Download PDF</a>
        <a class="button" href="./N-Methyl-Cyclazodone-Human-Use-Analysis.pdf" target="_blank" rel="noopener">View in browser</a>
      </p>
      <p class="small">
        Title: N‑Methyl‑Cyclazodone: A Pharmacological and Toxicological Assessment of a Novel Psychoactive Stimulant<br/>
        Version: 1.0 • Last updated: 2025‑08‑21<br/>
        Author: Tamás Arany • Gemini Deep Research • Contact: pharmacology@catom.dev
      </p>
    </section>
  </main>

  <footer>
    <div>© <span id="year"></span> Gemini Deep Research. All rights reserved.</div>
    <div class="small">This page is for research and educational purposes only. No medical or legal advice is provided.</div>
  </footer>

  <script>
    document.getElementById('year').textContent = new Date().getFullYear();
  </script>
</body>
</html>
